 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| «12...234567891011121314» |
- | Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
Trial completion: Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase (clinicaltrials.gov) - Sep 29, 2014
P4, N=25, Completed, Sponsor: Halozyme Therapeutics
Active, not recruiting --> Completed
- Victoza (liraglutide) / Novo Nordisk
Trial primary completion date: Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting (clinicaltrials.gov) - Sep 11, 2014
P1, N=17, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Jan 2015
- |||| Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
Trial completion, Enrollment change, Trial primary completion date: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 21, 2014
P2, N=132, Completed, Sponsor: Halozyme Therapeutics
Trial primary completion date: Jun 2014 --> Jan 2015 Active, not recruiting --> Completed | N=110 --> 132 | Trial primary completion date: Sep 2013 --> Aug 2011
- | New P4 trial: Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (clinicaltrials.gov) - Aug 19, 2014
P4, N=200, Recruiting, Sponsor: Mackay Memorial Hospital
- | Tresiba (insulin degludec) / Novo Nordisk
New P4 trial: HypoDeg: Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (clinicaltrials.gov) - Jul 16, 2014
P4, N=175, Not yet recruiting, Sponsor: Nordsjaellands Hospital
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open, Surgery: Linagliptin Inpatient Trial (clinicaltrials.gov) - Jul 8, 2014
P4, N=280, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | N=110 --> 132 | Trial primary completion date: Sep 2013 --> Aug 2011 Not yet recruiting --> Recruiting
- Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=2134, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2004 --> Oct 2006
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: Point-of-Care Glucose Testing and Insulin Supplementation (clinicaltrials.gov) - Jun 6, 2014
P=N/A, N=200, Completed, Sponsor: Emory University
Trial primary completion date: Oct 2004 --> Oct 2006 N=250 --> 200
- NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Point-of-Care Glucose Testing and Insulin Supplementation (clinicaltrials.gov) - Jun 6, 2014
P=N/A, N=200, Completed, Sponsor: Emory University
N=250 --> 200 Recruiting --> Completed
- Lantus (insulin glargine) / Sanofi
Clinical: REACT4SENSOR: Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=10, Enrolling by invitation, Sponsor: Medical University of Graz
- Victoza (liraglutide) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: PILGRIM: Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus (clinicaltrials.gov) - May 12, 2014
P=N/A, N=315, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Completed Trial primary completion date: Jul 2015 --> Dec 2015
- Victoza (liraglutide) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date: PILGRIM: Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus (clinicaltrials.gov) - May 12, 2014
P=N/A, N=315, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial primary completion date: Jul 2015 --> Dec 2015 Trial completion date: Aug 2015 --> Mar 2016
- Victoza (liraglutide) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: PILGRIM: Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus (clinicaltrials.gov) - May 12, 2014
P=N/A, N=315, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial completion date: Aug 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- Apidra (insulin glulisine) / Sanofi
Enrollment change: The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children (clinicaltrials.gov) - Apr 2, 2014
P4, N=16, Completed, Sponsor: Spectrum Health Hospitals
Not yet recruiting --> Recruiting N=24 --> 16
- Apidra (insulin glulisine) / Sanofi
Trial completion: The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children (clinicaltrials.gov) - Apr 2, 2014
P4, N=16, Completed, Sponsor: Spectrum Health Hospitals
N=24 --> 16 Recruiting --> Completed
- NovoLog (insulin aspart) / Novo Nordisk
New P3 trial: WP6-1: Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital (clinicaltrials.gov) - Mar 31, 2014
P3, N=15, Not yet recruiting, Sponsor: Centre d
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Insulin by Jet-injection for Hyperglycemia in Diabetes (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=20, Recruiting, Sponsor: University Medical Center Nijmegen
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Lusduna (insulin glargine biosimilar) / Samsung
Enrollment open: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) (clinicaltrials.gov) - Mar 2, 2014
P1, N=130, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | NovoLog Mix 70/30 (insulin aspart protamine 70%/insulin aspart 30%) / Novo Nordisk, BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
Trial completion, Combination therapy: Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes (clinicaltrials.gov) - Feb 22, 2014
P4, N=102, Completed, Sponsor: Steno Diabetes Center
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- ||| Lusduna (insulin glargine biosimilar) / Samsung
New P1 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) (clinicaltrials.gov) - Feb 9, 2014
P1, N=130, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Trial completion: Action to Control Cardiovascular Risk in Diabetes (ACCORD) (clinicaltrials.gov) - Feb 6, 2014
P3, N=10251, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- metformin / Generic mfg.
Enrollment change: CIMT: The Copenhagen Insulin and Metformin Therapy Trial (clinicaltrials.gov) - Feb 1, 2014
P4, N=415, Completed, Sponsor: Steno Diabetes Center
Active, not recruiting --> Completed N=900 --> 415
- metformin / Generic mfg.
Trial completion: CIMT: The Copenhagen Insulin and Metformin Therapy Trial (clinicaltrials.gov) - Feb 1, 2014
P4, N=415, Completed, Sponsor: Steno Diabetes Center
N=900 --> 415 Active, not recruiting --> Completed
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: Carbohydrate Consumption as a Factor in Aspart Dosing (clinicaltrials.gov) - Jan 27, 2014
P4, N=30, Completed, Sponsor: Rush University Medical Center
Active, not recruiting --> Completed N=100 --> 30
- NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Carbohydrate Consumption as a Factor in Aspart Dosing (clinicaltrials.gov) - Jan 27, 2014
P4, N=30, Completed, Sponsor: Rush University Medical Center
N=100 --> 30 Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial, Surgery: Linagliptin Inpatient Trial (clinicaltrials.gov) - Dec 5, 2013
P4, N=280, Not yet recruiting, Sponsor: Emory University
- Victoza (liraglutide) / Novo Nordisk
Enrollment closed: Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics (clinicaltrials.gov) - Nov 7, 2013
P4, N=36, Active, not recruiting, Sponsor: Mountain Diabetes and Endocrine Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Trial completion: VIISTA: Veterans Inpatient Insulin Study and Transition to Outpatient Therapy (clinicaltrials.gov) - Oct 22, 2013
P4, N=120, Completed, Sponsor: Dennis G. Karounos, M.D.
Recruiting --> Active, not recruiting Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open, Surgery: Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 3, 2013
P4, N=280, Recruiting, Sponsor: Emory University
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment closed: CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - Aug 7, 2013
P4, N=400, Active, not recruiting, Sponsor: Halozyme Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
Enrollment closed: Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase (clinicaltrials.gov) - Jul 9, 2013
P4, N=25, Active, not recruiting, Sponsor: Halozyme Therapeutics
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- |||| NovoLog (insulin aspart) / Novo Nordisk
Trial completion: ICHO: Prandial Insulin Dosing in Hospitalized Patients (clinicaltrials.gov) - May 27, 2013
P4, N=126, Completed, Sponsor: Kathleen Dungan
Completed --> Active, not recruiting Active, not recruiting --> Completed
- NovoLog (insulin aspart) / Novo Nordisk
New P4 trial: Investigation of the resistance exerted by the tissue upon the insulin solution entering the tissue (hydraulic tissue resistance) at the site of administration and determine its relationship to the ability of the tissue to absorb the administered insulin (EUDRACT) - May 12, 2013
P4, N=10, Ongoing, Sponsor: Medizinische Universit
- ||||| New P4 trial: CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - May 6, 2013
P4, N=400, Active, not recruiting, Sponsor: Halozyme Therapeutics
- | Januvia (sitagliptin) / Merck (MSD)
New P4 trial, Surgery: Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes (clinicaltrials.gov) - May 1, 2013
P4, N=280, Recruiting, Sponsor: Emory University
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P4 trial: GlyCEDIA: Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients (clinicaltrials.gov) - Apr 9, 2013
P4, N=38, Completed, Sponsor: Centre Europeen d'Etude du Diabete
- ||||||| Humalog pen (insulin lispro) / Eli Lilly
Trial completion: Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy (clinicaltrials.gov) - Mar 25, 2013
P3, N=120, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog (clinicaltrials.gov) - Mar 14, 2013
P1, N=43, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Compliance: INSUVASC: INSUlin Regimens and VASCular Functions (clinicaltrials.gov) - Feb 19, 2013
P=N/A, N=42, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Humalog pen (insulin lispro) / Eli Lilly, Apidra (insulin glulisine) / Sanofi
Trial completion, Real-world evidence, Real-world: Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=107, Completed, Sponsor: University of Florida
Recruiting --> Completed Recruiting --> Completed
- NovoLog (insulin aspart) / Novo Nordisk
Trial initiation date: Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II) (clinicaltrials.gov) - Jan 27, 2013
P2, N=10, Completed, Sponsor: Aarhus University Hospital
Recruiting --> Completed Initiation date: Feb 2012 --> May 2012
- NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II) (clinicaltrials.gov) - Jan 27, 2013
P2, N=10, Completed, Sponsor: Aarhus University Hospital
Initiation date: Feb 2012 --> May 2012 Not yet recruiting --> Completed
- Victoza (liraglutide) / Novo Nordisk
Enrollment open: Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting (clinicaltrials.gov) - Jan 24, 2013
P1, N=17, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Enrollment closed: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (clinicaltrials.gov) - Jan 24, 2013
P4, N=35, Active, not recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: Mechanisms of Insulin Facilitation of Memory (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=25, Recruiting, Sponsor: University of Texas at Austin
Recruiting --> Active, not recruiting N=15 --> 25
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Mechanisms of Insulin Facilitation of Memory (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=25, Recruiting, Sponsor: University of Texas at Austin
N=15 --> 25 Completed --> Recruiting
- | Victoza (liraglutide) / Novo Nordisk
New P1 trial: Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting (clinicaltrials.gov) - Dec 20, 2012
P1, N=17, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- Enrollment open, Post-transplantation: PTHG: Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (clinicaltrials.gov) - Oct 16, 2012
P4, N=120, Recruiting, Sponsor: Vancouver General Hospital
Completed --> Recruiting Not yet recruiting --> Recruiting
- NovoLog (insulin aspart) / Novo Nordisk
Clinical: Point-of-Care Glucose Testing and Insulin Supplementation (clinicaltrials.gov) - Oct 4, 2012
P=N/A, N=250, Recruiting, Sponsor: Emory University
- | NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: Comparison of Two Insulin Aspart Formulations in Healthy Volunteers (clinicaltrials.gov) - Oct 1, 2012
P1, N=24, Completed, Sponsor: Novo Nordisk